Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Phase II Study of Prophylactic TPO Combined with Bone Marrow-sparing Intensity-modulated Radiotherapy to Reduce Platelet Inhibition in Patients with Esophageal Cancer Undergoing Concurrent Chemoradiotherapy

NCT05944809 is registered in ClinicalTrials.gov with JIANYANG WANG as lead sponsor.

NCT NCT05944809
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05944809 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Phase II Study of Prophylactic TPO Combined with Bone Marrow-sparing Intensity-modulated Radiotherapy to Reduce Platelet Inhibition in Patients with Esophageal Cancer Undergoing Concurrent Chemoradiotherapy
Lead sponsor
JIANYANG WANG
Phase
Phase 2
Overall status
Completed
Start date
July 20, 2023
Completion date
December 31, 2024
Enrollment
32 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

concurrent chemoradiotherapy, esophageal cancer, intensity-modulated radiation therapy, thrombocytopenia